Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CELL SOURCE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MIDDLE EAST & AFRICA MEDICAL CARTS MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.2 REGULATION IN CANADA
5.3 REGULATION IN EUROPE
5.4 REGULATION IN INDIA
5.5 REGUALTION IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT
6.2 RESTRAINT
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE
6.3.3 SURGE IN HEALTHCARE EXPENDITURE
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE
6.4.2 LACK OF SKILLED PROFESSIONALS
6.4.3 STRINGENT REGULATORY FRAMEWORK
7 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS BY MANUFACTURERS
7.5 CONCLUSION
8 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE
8.1 OVERVIEW
8.2 SKIN CELLS
8.2.1 FIBROBLAST
8.2.2 KERATINOCYTES
8.2.3 ADIPOSE DERIVED STEM CELLS
8.2.4 HEPATOCYTES
8.2.5 MELANOCYTES
8.2.6 NEURAL STEM CELLS
8.2.7 OTHERS
8.3 BLOOD CELLS
8.3.1 PERIPHERAL BLOOD
8.3.2 CORD BLOOD ENDOTHELIAL CELLS
8.3.3 CORD BLOOD STEM CELLS
8.3.4 OTHERS
9 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE
9.1 OVERVIEW
9.2 HUMAN IPSCS
9.3 MOUSE IPSCS
10 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 CONSUMABLES & KITS
10.2.1 REPROGRAMMING KITS
10.2.2 MEDIA
10.2.3 TRANSFECTION KITS
10.2.4 CELL IDENTIFICATION KITS
10.2.5 ACCESSORIES
10.2.6 OTHERS
10.3 SERVICES
10.4 INSTRUMENTS
10.4.1 IMAGING SYSTEMS
10.4.2 ELECTROPORATION DEVICE
10.4.3 INCUBATORS
10.4.4 OTHERS
11 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DRUG DISCOVERY AND DEVELOPMENT
11.3 ACADEMIC RESEARCH
11.4 DISEASE MODELLING
11.5 CELLULAR THERAPY
11.6 REGENERATIVE MEDICINE
11.7 TOXICOLOGY SCREENING
11.8 STEM CELL BANKING
11.9 3D BIOPRINTING
11.1 OTHERS
12 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER
12.1 OVERVIEW
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
12.3 RESEARCH LABORATORIES
12.4 DIAGNOSTIC LABORATORIES
12.5 OTHERS
13 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SOUTH AFRICA
14.1.2 SAUDI ARABIA
14.1.3 UAE
14.1.4 EGYPT
14.1.5 ISRAEL
14.1.6 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 FUJIFILM CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.1.5.1 ACQUISITION
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.2.5.1 EVENT
17.2.5.2 ACQUISITION
17.3 LONZA.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.3.5.1 EXPANSION
17.4 MERCK KGAA
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.4.5.1 AGREEMENT
17.5 EVOTEC SE.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.5.1 AGREEMENT
17.5.5.2 COLLABORATION
17.6 APPLIED STEMCELL.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.6.3.1 PRODUCT LAUNCH
17.7 AXOL BIOSCIENCE LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.7.3.1 MERGER
17.7.3.2 PRODUCT LAUNCH
17.8 CELL APPLICATIONS, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.8.3.1 PARTNERSHIP
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.9.4.1 ACQUISITION
17.1 CITIUS PHARMACEUTICALS, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.10.3.1 AGREEMENT
17.11 CORNING INCORPORATED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 AGREEMENT
17.12 FATE THERAPEUTICS
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 CLINICAL TRIAL
17.13 GENECOPOEIA, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 HOPSTEM BIOTECHNOLOGY LLC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PARTNERSHIP
17.15 HORIZON DISCOVERY LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 LUMACYTE
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.16.3.1 COLLABORATION
17.17 R & D SYSTEMS, INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 REPROCELL INC.
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.18.3.1 COLLABORATION
17.18.3.2 FACILITY EXPANSION
17.18.3.3 SERVICE LAUNCH
17.19 TAKARA BIO INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.19.4.1 NEW FACILITY LAUNCH
17.2 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.20.4.1 ACQUISITION
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 46 SOUTH AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 47 SOUTH AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 48 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 56 SAUDI ARABIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 57 SAUDI ARABIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 58 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 66 UAE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 67 UAE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 68 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 UAE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 UAE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 76 EGYPT SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 77 EGYPT BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 78 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 EGYPT INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 EGYPT CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 86 ISRAEL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 87 ISRAEL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 88 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 ISRAEL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 91 ISRAEL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 92 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 93 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 REST OF MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 11 THE WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SKIN CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
FIGURE 15 PREVALENCE OF CHRONIC DISEASES
FIGURE 16 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
FIGURE 17 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2021
FIGURE 18 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2020-2029 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2022-2029)
FIGURE 20 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2021
FIGURE 22 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2021
FIGURE 26 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 28 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2021
FIGURE 30 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 32 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2021
FIGURE 34 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 36 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 38 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 39 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 40 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 42 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 43 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 44 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 45 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 46 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
